These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22911090)

  • 21. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
    Canton R; Morosini M; Enright MC; Morrissey I
    J Antimicrob Chemother; 2003 Dec; 52(6):944-52. PubMed ID: 14585861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone resistance in Streptococcus pneumoniae isolates in Germany from 2004-2005 to 2014-2015.
    Schmitz J; van der Linden M; Al-Lahham A; Levina N; Pletz MW; Imöhl M
    Int J Med Microbiol; 2017 Jun; 307(4-5):216-222. PubMed ID: 28506425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
    Iraurgui P; Torres MJ; Aznar J
    Enferm Infecc Microbiol Clin; 2012 Apr; 30(4):180-3. PubMed ID: 22365183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
    Patel SN; Melano R; McGeer A; Green K; Low DE
    Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
    Deshpande LM; Sader HS; Debbia E; Nicoletti G; Fadda G; Jones RN;
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):157-64. PubMed ID: 16423493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.
    Hsieh YC; Chang LY; Huang YC; Lin HC; Huang LM; Hsueh PR
    Clin Microbiol Infect; 2010 Jul; 16(7):973-8. PubMed ID: 19778298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
    Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
    Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
    Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of quinolone-resistant strains in Streptococcus pneumoniae isolated from paediatric patients since the approval of oral fluoroquinolones in Japan.
    Takeuchi N; Ohkusu M; Hoshino T; Naito S; Takaya A; Yamamoto T; Ishiwada N
    J Infect Chemother; 2017 Apr; 23(4):218-223. PubMed ID: 28159338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutant prevention concentrations of garenoxacin against Streptococcus pneumoniae isolates from otorhinolaryngological infections].
    Suzuki K; Kurono Y; Kobayashi T; Nishimura T; Baba S; Harabuchi Y; Fujisawa T; Yamanaka N; Ubukata K; Ikeda F
    Jpn J Antibiot; 2010 Aug; 63(4):312-8. PubMed ID: 21298864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluoroquinolone-resistant Streptococcus pneumoniae in Spain: activities of garenoxacin against clinical isolates including strains with altered topoisomerases.
    Morosini MI; Loza E; del Campo R; Almaraz F; Baquero F; Cantón R
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2692-5. PubMed ID: 12878544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.
    Stewart BA; Johnson AP; Woodford N
    J Med Microbiol; 1999 Dec; 48(12):1103-1106. PubMed ID: 10591164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.